$XBI $68.77 | +1.84%
Table of Contents:
Covid Updates
#MRNA -2.3% Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement source
Pipeline Updates
#VECT +11.1% VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease source
#ADVM +4.7% Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting source
#VIRX +3.9% Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting source
#AXSM +3.1% axsome therapeutics presents new data from the gemini trial demonstrating efficacy of axs-05 on anhedonia in patients with major depressive disorder source
#GMDA +2.8% Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel source
#VXRT +2.3% Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults source
#MYOV +1.8% Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® source
#CNTA -27.8% Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) source
#IMUX -48.8% Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update source
#AGLE -51.3% Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#LCTX +6.5% Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology source
Posted by JM